Lutetium Lu-177

Nuclear medicine integrates diagnostic and therapeutic capabilities in oncology, using radiopharmaceuticals for precise cancer detection and treatment. It offers early diagnosis, targeted radiation, and personalized care, revolutionizing cancer diagnostics and treatment. Recent innovations, including AI and theranostics, enhance outcomes, though challenges like accessibility persist.

Pluvicto, a new prostate cancer treatment using lutetium-177, costs $27,000 per dose, totaling $135,000 for an average five-dose treatment. The pan-Canadian Pharmaceutical Alliance (pCPA) ended negotiations with Novartis, leaving patients to fund the treatment themselves. Health Canada approved Pluvicto in 2022, but coverage is unavailable in B.C. without third-party insurance or private payment. Patients and advocates call for renewed negotiations to make the treatment accessible.

101,746 AE reports analyzed, 68,492 (67.3%) female, 32,547 (32.0%) male; average age 69.8 ± 11.5 (female), 71.5 ± 11.2 (male). Report numbers fluctuated since 2004, peaking 2010-2012 and 2018-2019. Most reports from America (62.3% female, 55.4% male), mainly hospitalization (51.3% female, 51.2% male). Multiple sclerosis most reported AE (14.2% female, 6.2% male). Signals detected using ROR and BCPNN algorithms; top signals varied by sex. Sex differences in signal numbers noted in 2nd-level ATC classes. F/M ratio analysis on shared signals showed 33 positive for females, 38 for males, 48 no difference. Specific drugs showed stronger associations with falls in one sex over the other across various ATC classifications.

Peptide-based cancer therapies show promise with multifunctional peptides for diagnosis, targeting, and treatment (theranostics). AI and machine learning aid in peptide sequence design, and integration with other therapies enhances treatment. Clinical trials highlight peptide-drug conjugates and imaging agents. Peptides offer high specificity, reduced toxicity, and adaptable characteristics. Over 30 peptide drugs approved globally. Peptide attributes include compact structure and strong selectivity. Examples: goserelin for breast and prostate cancer, octreotide for neuroendocrine tumors. Market report highlights include a $18 billion opportunity, 30+ approved drugs, and 230+ drugs in clinical trials. Peptides transform diagnostics with radiolabeled peptides for PET imaging. Therapeutic approaches include targeting cancer cells, delivering cytotoxic agents, and peptide vaccines. Innovations in peptide engineering and delivery mechanisms expand their scope. Personalized medicine and ongoing research position peptides as key in future cancer care.

The peptide cancer drug market is projected to exceed $18 billion, with over 30 approved drugs and 230 in clinical trials. Peptides offer high specificity and reduced toxicity, enabling targeted cancer therapies and diagnostics. Innovations include peptide-drug conjugates, imaging agents, and peptide vaccines, enhancing treatment efficacy and personalized medicine.

Global peptide cancer drug market to exceed US$ 18 billion by 2030, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, with major players like Novartis and emerging firms driving innovation.

Global peptide cancer drug market expected to exceed $18 billion, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, combining biologics' specificity with small molecules' cost-effectiveness. Major players include Novartis and Roche, with US leading R&D, supported by FDA's expedited approvals.

Canadian researchers are part of global efforts to test targeted alpha therapy, a new cancer treatment using radioactive alpha particles to kill cancer cells more effectively and with less damage to healthy tissue. Several therapies are in final stages of testing and could be approved by Health Canada within a few years. Potential applications include pancreatic, prostate, breast, and neuroendocrine cancers. Challenges include production of rare radioactive isotopes and high costs, with treatments expected to cost tens of thousands of dollars per dose.

Radiotheranostics merges diagnostic and therapeutic capabilities, enhancing precision medicine in oncology through radiopharmaceuticals, with potential applications in cardiology and neurology.